Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513
- 1 July 2002
- journal article
- clinical trial
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 53 (4) , 980-986
- https://doi.org/10.1016/s0360-3016(02)02817-1
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Phase I Study of Topotecan Plus Cranial Radiation for Glioblastoma Multiforme: Results of Radiation Therapy Oncology Group Trial 9507Journal of Clinical Oncology, 2001
- Topotecan for the Treatment of Recurrent or Progressive Central Nervous System Tumors – A Pediatric Oncology Group Phase II StudyJournal of Neuro-Oncology, 1999
- Topotecan: An Oncologist's ViewThe Oncologist, 1998
- Phase II study of topotecan in patients with recurrent malignant gliomaAnnals of Oncology, 1996
- Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenograftsCancer Chemotherapy and Pharmacology, 1994
- Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma TrialsJNCI Journal of the National Cancer Institute, 1993
- Interaction of topoisomerase I inhibitors with radiation in cis‐diamminedichloroplatinum(II)‐sensitive and ‐resistantcells In Vitro and in the fsaiic fibrosarcoma In VivoInternational Journal of Cancer, 1993
- Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cellsInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase IInternational Journal of Radiation Oncology*Biology*Physics, 1992
- On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complexBiochemistry, 1989